).
Whole brain radiotherapy (WBRT) is usually avoided in the initial treatment of patients with primary central nervous system lymphoma (PCNSL). Although efficacious, combined modality therapy has been abandoned by most physicians due to reports of neurotoxicity in patients who received it. WBRT has been so vilified that many physicians will not even consider it when a patient # The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
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Neuro-Oncology 16 (8) , 1032, 2014 doi:10.1093/neuonc/nou135 has primary chemorefractory disease. It is time to review this approach and clarify the potential role of WBRT in patients with PCNSL.
Historically, WBRT was the sole treatment for the disease we now recognize as PCNSL. Previously called microglioma or reticulum cell sarcoma, it was only in the 1970's that the lymphoid origin of PCNSL was recognized. WBRT was, at the time, the standard treatment for all primary CNS neoplasms, including malignant glioma; it was often combined with a boost to areas of bulky disease. Eventually, several trials showed that limited field radiation was as effective and less toxic for malignant gliomas, and WBRT was abandoned. WBRT continued to be used in the treatment of PCNSL largely because insufficient patient numbers obviated a comprehensive study. However, the first trial completed by the Radiation Therapy Oncology Group (RTOG) proved that WBRT plus a focal boost as sole therapy effectively caused tumor regression and prolonged survival but only achieved a median survival of about 1 year, largely because of tumor regrowth. 1 Most importantly, they and others identified that tumor recurred as frequently within as outside the boosted field, supporting the need for whole brain but eliminating the need for a boost to areas of bulky disease. 1, 2 Subsequent studies in Japan demonstrated that focal RT resulted in increased relapse in regions of the brain excluded from the RT port, confirming the need for WBRT in PCNSL when RT is used. 3 Chemotherapy was added to WBRT in the 1980's when the incidence of PCNSL was increasing. WBRT was retained because it was the only recognized effective therapeutic modality. However, it quickly became clear that combination chemotherapy regimens effective for comparable systemic lymphomas (eg, CHOP [cyclophosphamide/hydroxyldaunorubicin/oncovin/prednisone]) when added to WBRT did not improve survival over WBRT alone. High-dose methotrexate was effective in the treatment of the occasional patient with CNS metastatic disease from lymphoma or lymphoid leukemias, and when added to WBRT it enhanced response and prolonged survival in all phase II trials of PCNSL conducted to date.
Combined modality therapy yielded for the first time prolonged disease-free survival, but at the cost of delayed cognitive impairment that could be progressive and devastating in a proportion of patients. The elderly were most vulnerable, but there was no safe age threshold. The incidence of neurotoxicity varied widely depending upon the method of identification, either clinically or with formal psychometric testing, the age distribution of treated patients, and the length of follow-up; an incidence of 30% has been reported in a series of studies. 4, 5 The simple frequency is often provided as a measure of the toxicity of a given regimen, but this is an inaccurate means of assessing the true risk of neurotoxicity from combined modality therapy. A competing risk analysis adjusts for those patients who relapse. With such a statistical analysis, it becomes clear that 24% of patients develop this complication at 5 years, and the greatest vulnerability for neurocognitive impairment occurs within the first 3 years of diagnosis, plateauing beyond that time. 6 Even more significant is the high risk of recurrent disease that is twice the risk of neurotoxicity. Thus, uncontrolled PCNSL is the primary hurdle to both survival and good quality of life in most PCNSL patients. Prevention of relapse should be the primary research focus.
So, can WBRT contribute to disease control? There has been only a single phase III randomized study of patients with PCNSL, conducted in Germany, in which all patients received highdose methotrexate with or without ifosfamide. Those who achieved a complete response (CR) were then randomized to receive 45 Gy WBRT or observation; those patients who failed to achieve a CR were randomized to 45 Gy WBRT or high-dose cytarabine. 7 The study was complicated and failed to meet its predetermined noninferiority endpoint despite 551 patients being enrolled. However, the data demonstrated that patients who received WBRT had a significantly longer progression-free survival (PFS) of 18 months compared with those who did not receive WBRT (12 mo). Because there was no difference in overall survival (OS), many have advocated that WBRT does not add anything other than toxicity and can be eliminated or replaced with intensified chemotherapy, including stem cell transplant.
Let us examine each issue. First, does WBRT contribute to survival? The German study failed to demonstrate a survival benefit; however, there was a 34% noncompliance in the WBRT arm contrasted with the complete compliance seen in the chemotherapy-alone arm, making the comparison difficult. Furthermore, CR patients who received chemotherapy plus WBRT frequently did not receive salvage treatment, based upon a median PFS of 36.3 months and a nearly identical median OS of 38.8 months, compared with patients who received chemotherapy alone, where the median PFS was 21.5 months and median OS 39.4 months. We have no information on the cause of death in the 2 treatment arms. If PFS was prolonged, what did these patients die of? In other studies examining this question, it is clear that patients receiving WBRT die of neurotoxicity at a greater rate, whereas those who receive chemotherapy alone die of tumor progression, suggesting that combined modality therapy is effective at tumor elimination but at an unacceptably high cost to the brain. 5 We have limited data on the neurotoxicity profile of patients in the German study (see below), but the neurocognitive cost of tumor relapse is underestimated and has been documented to be high in other CNS malignancies. All of these issues could have affected the survival and toxicity dynamics.
Thus, WBRT improves disease control but contributes to neurotoxicity that often compromises the patient in an unacceptable way. So, should WBRT be avoided at any cost? A number of years ago we began to explore whether we could leverage the diseasekilling benefits of WBRT without the toxicity by reducing the dose in patients who achieved a CR to upfront chemotherapy. In a phase II single institution study we could demonstrate that 65% of patients were eligible for reduced-dose WBRT, and those who received it had a median PFS of 7.7 years, median OS not reached (5-y OS of 80%), and no cognitive impairment clinically or on formal psychometric testing. 8, 9 This approach is being tested by the RTOG in a randomized phase II setting in which all patients will continue to receive psychometric testing to assess the cognitive consequences of relapse as well as treatment.
Second, does elimination of WBRT prevent neurotoxicity? It is well established that WBRT can cause cognitive impairment. However, there has been a misguided belief that intensive chemotherapy for PCNSL is free of neurotoxicity. There is mounting evidence and growing acceptance that systemic chemotherapy can cause cognitive dysfunction. Such "chemo brain" has been best studied in patients with breast cancer receiving adjuvant therapy, but "chemo brain" appears to be caused by a number of different systemic agents. 10 The mechanisms are unclear and multifactorial but likely include many of the same mechanisms by which WBRT contributes to cognitive loss, such as DeAngelis: Whither whole brain radiotherapy for primary CNS lymphoma? reduced neural stem cell number and function. Studies of cognitive functions after treatment for PCNSL demonstrate that impairment may be more severe when WBRT has been added to systemic chemotherapy, but patients receiving chemotherapy alone often have evidence of impairment as well. 11 Thus, the difference may be more a matter of degree than an all-or-nothing proposition as it has been portrayed.
Furthermore, many of the intensive chemotherapy regimens used to "replace" the anticancer effect of WBRT in PCNSL are themselves quite toxic, causing both acute systemic toxicity and delayed neurotoxicity. Acute toxicities usually include myelosuppression and organ failure, some of which lead to death. The recent report of intensive etoposide and cytarabine for consolidation in PCNSL identified an 81% incidence of grade 4 toxicity and a 4% incidence of death during this part of the regimen. 12 This same regimen used for induction prior to transplant in relapsed PCNSL had a 7% death rate. 13 In the German study, only 79 patients were evaluable for clinically defined neurotoxicity; neurotoxicity was observed in 49% of patients who received WBRT and 26% of those who received chemotherapy alone. Thus, while WBRT increased the risk of cognitive impairment, the proportion of those who developed neurotoxicity from chemotherapy alone was sizable and unexpected. Finally, high-dose chemotherapy with autologous stem cell transplant has been touted as an effective approach to PCNSL therapy, particularly for younger patients. However, transplantation itself can cause cognitive impairment, and this has not been studied in PCNSL patients. 14, 15 WBRT remains effective treatment for patients with PCNSL because it reduces relapse and contributes to disease control. It does carry the potential for neurotoxicity, particularly in older patients and when used at full dose. However, if used at a lower dose for patients who have responded to initial chemotherapy, it contributes to a durable remission relatively free of cognitive consequences. WBRT should be an option for patients not enrolled in a clinical trial or who cannot tolerate intensive chemotherapy for consolidation. It is clear that there is no single approach that is best for all patients. Eliminating WBRT from the PCNSL armamentarium would be a mistake and disservice to our patients.
